Cargando…

Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study

BACKGROUND: The development of cancer has been associated with epigenetic alterations such as aberrant histone deacetylase (HDAC) activity. It was recently reported that valproic acid is an effective inhibitor of histone deacetylases and as such induces tumor cell differentiation, apoptosis, or grow...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chavez-Blanco, Alma, Segura-Pacheco, Blanca, Perez-Cardenas, Enrique, Taja-Chayeb, Lucia, Cetina, Lucely, Candelaria, Myrna, Cantu, David, Gonzalez-Fierro, Aurora, Garcia-Lopez, Patricia, Zambrano, Pilar, Perez-Plasencia, Carlos, Cabrera, Gustavo, Trejo-Becerril, Catalina, Angeles, Enrique, Duenas-Gonzalez, Alfonso
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2005
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1198251/ https://www.ncbi.nlm.nih.gov/pubmed/16001982 http://dx.doi.org/10.1186/1476-4598-4-22

Ejemplares similares

Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines
por: Chavez-Blanco, Alma, et al.
Publicado: (2006)

Epigenetic therapy with hydralazine and valproate associated to cisplatin chemoradiation in FIGO stage IIIB. A phase II study
por: Candelaria, Myrna, et al.
Publicado: (2007)

A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors
por: Candelaria, Myrna, et al.
Publicado: (2007)

A proof-of-principle study of epigenetic therapy with hydralazine and magnesium valproate plus doxorubicin cyclophosphamide as neoadjuvant therapy for locally advanced breast cancer
por: Arce, Claudia, et al.
Publicado: (2007)

A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes
por: Zambrano, Pilar, et al.
Publicado: (2005)

Serum nucleosomes during neoadjuvant chemotherapy in patients with cervical cancer. Predictive and prognostic significance
por: Trejo-Becerril, Catalina, et al.
Publicado: (2005)

A Proof-Of-Principle Study of Epigenetic Therapy Added to Neoadjuvant Doxorubicin Cyclophosphamide for Locally Advanced Breast Cancer
por: Arce, Claudia, et al.
Publicado: (2006)

DNA Methylation-Independent Reversion of Gemcitabine Resistance by Hydralazine in Cervical Cancer Cells
por: Candelaria, Myrna, et al.
Publicado: (2012)

HER2 expression in cervical cancer as a potential therapeutic target
por: Chavez-Blanco, Alma, et al.
Publicado: (2004)

Hydralazine target: From blood vessels to the epigenome
por: Arce, Claudia, et al.
Publicado: (2006)

Radiosensitizers in cervical cancer. Cisplatin and beyond
por: Candelaria, Myrna, et al.
Publicado: (2006)

Expression of platelet derived growth factor family members and the potential role of imatinib mesylate for cervical cancer
por: Taja-Chayeb, Lucia, et al.
Publicado: (2006)

Identification of a novel germ-line mutation in the TP53 gene in a Mexican family with Li-Fraumeni syndrome
por: Taja-Chayeb, Lucia, et al.
Publicado: (2009)

Antimetastatic effect of epigenetic drugs, hydralazine and valproic acid, in Ras-transformed NIH 3T3 cells
por: Pérez-Cárdenas, Enrique, et al.
Publicado: (2018)

The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study
por: de la Cruz-Hernández, Erick, et al.
Publicado: (2007)

Epigenetics of cervical cancer. An overview and therapeutic perspectives
por: Dueñas-González, Alfonso, et al.
Publicado: (2005)

Global DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine
por: Segura-Pacheco, Blanca, et al.
Publicado: (2006)

Antitumor Effects of Systemic DNAse I and Proteases in an In Vivo Model
por: Trejo-Becerril, Catalina, et al.
Publicado: (2016)

Polymorphisms of the thiopurine methyl transferase gene in healthy and acute lymphoblastic leukemia mestizos
por: Candelaria, Myrna, et al.
Publicado: (2007)

Chemoradiation with cisplatin followed by either brachytherapy or radical hysterectomy. A non-randomized comparison in FIGO stages IB2-IIA
por: Cetina, Lucely, et al.
Publicado: (2007)

Brachytherapy versus radical hysterectomy after external beam chemoradiation: a non-randomized matched comparison in IB2-IIB cervical cancer patients
por: Cetina, Lucely, et al.
Publicado: (2009)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Sodium valproate-induced congenital cardiac abnormalities in mice are associated with the inhibition of histone deacetylase
por: Wu, Gang, et al.
Publicado: (2010)

Routine management of locally advanced cervical cancer with concurrent radiation and cisplatin. Five-year results
por: Cetina, Lucely, et al.
Publicado: (2006)

Cancer Progression Mediated by Horizontal Gene Transfer in an In Vivo Model
por: Trejo-Becerril, Catalina, et al.
Publicado: (2012)

Pre-exenterative chemotherapy, a novel therapeutic approach for patients with persistent or recurrent cervical cancer
por: Lopez-Graniel, Carlos, et al.
Publicado: (2005)

Radiation-sparing managements for cervical cancer: a developing countries perspective
por: Candelaria, Myrna, et al.
Publicado: (2006)

Concurrent chemoradiation with carboplatin for locally advanced cervical cancer at high-risk for developing cisplatin-induced renal dysfunction
por: Cetina, Lucely, et al.
Publicado: (2007)

Histone deacetylases, microRNA and leptin crosstalk in pancreatic cancer
por: Tchio Mantho, Cynthia I, et al.
Publicado: (2017)

Beyond Histone and Deacetylase: An Overview of Cytoplasmic Histone Deacetylases and Their Nonhistone Substrates
por: Yao, Ya-Li, et al.
Publicado: (2011)

Sex-Dependent Effects of the Histone Deacetylase Inhibitor, Sodium Valproate, on Reversal Learning After Developmental Arsenic Exposure
por: Tyler, Christina R. Steadman, et al.
Publicado: (2018)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

The effects of DNA methylation and histone deacetylase inhibitors upon the human papillomavirus early genes expression in cervical cancer. An in vitro and clinical study
por: de la Cruz-Hernandez, Erik, et al.
Publicado: (2007)

Prognostic significance of pathological response after neoadjuvant chemotherapy or chemoradiation for locally advanced cervical carcinoma
por: Candelaria, Myrna, et al.
Publicado: (2006)

Chemical Phylogenetics of Histone Deacetylases
por: Bradner, James E., et al.
Publicado: (2010)

Histone deacetylases in viral infections
por: Herbein, Georges, et al.
Publicado: (2010)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

Histone deacetylase signaling in cardioprotection
por: Lehmann, Lorenz H., et al.
Publicado: (2013)

Histone deacetylase 6 in cancer
por: Li, Ting, et al.
Publicado: (2018)

Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
por: Yan, Wensheng, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ad7ss8hpaj6trd2u1711u3tqgj